Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NYSE | Common Stock
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 12, 24 | -0.72 Increased by +39.50% | -0.80 Increased by +10.00% |
| Mar 29, 24 | -2.24 Decreased by -113.33% | -1.30 Decreased by -72.31% |
| Nov 8, 23 | -1.63 Decreased by -75.27% | -1.09 Decreased by -49.54% |
| Aug 14, 23 | -1.07 Increased by 0.00% | -1.14 Increased by +6.14% |
| May 10, 23 | -1.19 Decreased by -65.28% | -0.33 Decreased by -260.61% |
| Mar 1, 23 | -1.05 Decreased by -40.00% | -1.05 |
| Nov 8, 22 | -0.93 Decreased by -165.71% | -1.01 Increased by +7.92% |
| Aug 8, 22 | -1.07 Decreased by -214.71% | -0.64 Decreased by -67.19% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.07 M Increased by +96.38% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -22.21 M Decreased by -635.39% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.72 M Decreased by -95.81% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.54 M Decreased by -10.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -29.44 M Decreased by -402.90% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -3.02 M Increased by +48.93% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -7.52 M Decreased by -163.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -8.65 M Decreased by -242.47% | Decreased by N/A% Decreased by N/A% |